GlassScriptPhysician profile
Daniel Zilberbrand
NPI 1275021099
$3,631.63
in general payments reported to CMS, 2019-2025
10 companies · $946 in 2025
The $946 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $577 · 2021: $904 · 2022: $430 · 2023: $260 · 2024: $515 · 2025: $946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,720.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $1,315.50 | 2020-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Tactile Systems Technology INC | $693.63 | 2022-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Stryker Corporation | $536.37 | 2020-2025 | Citrefix, Augment Injectable, Flexband |
| Medical Device Business Services, INC. | $259.99 | 2021 | |
| Globus Medical, INC. | $184.12 | 2025 | Senza |
| Nevro Corp. | $165.85 | 2022 | |
| Davol INC. | $160.29 | 2024 | Arista Ah Flexitip |
| Smith+Nephew, INC. | $157.87 | 2021-2023 | Grafix Pl |
| Averitas Pharma INC. | $105.47 | 2024 | Qutenza |
| Abbvie INC. | $52.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Zilberbrand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.